Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panzytrat 25000 versus Kreon 25000 crossover study in cystic fibrosis with exocrine pancreatic insufficiency
2010-019267-11Phase 4Completed
- Sponsor
- Axcan Pharma Inc.
- Start
- Oct 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pancrelipase in exocrine pancreatic insufficiency (EPI) and cystic fibrosis (CF) (2 arms), sponsored by Axcan Pharma Inc. Primary endpoint: Coefficient of fat absorption. Started Oct 2010; status: completed.
02
Drugs
pancrelipase
03
Conditions
exocrine pancreatic insufficiency (EPI)cystic fibrosis (CF)
Beyond the preview
Go deeper on 2010-019267-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019267-11.